Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juan Pedro-Botet

Showing results (11-20 of 240) with videos related to

Pageof 24
Sort By:
Obesity (Silver Spring, Md.)|January 11, 2018
Neurotensin and Nonalcoholic Fatty Liver Disease: Beyond ObesityJuan Pedro-Botet, David Benaiges
Medicina Clinica|March 12, 2020
LDL cholesterol in one stepJuan Pedro-Botet, Elisenda Climent
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|November 26, 2021
Warning: a short circuit has been detected in the prescription of PCSK9 inhibitorsJuan Pedro-Botet, Elisenda Climent
Medicina Clinica|March 15, 2003
[Hypertriglyceridemia as a cardiovascular risk factor. The end of a controversy?]Juan Rubiés-Prat, Juan Pedro-Botet
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|May 10, 2021
Therapeutic targets in the treatment of dyslipidaemias: From statins to PCSK9 inhibitors. Unmet needsJosé López-Miranda, Juan Pedro-Botet
Lancet (London, England)|May 7, 2017
Statin-associated muscle symptoms: beware of the nocebo effectJuan Pedro-Botet, Juan Rubiés-Prat
Medicina Clinica|February 28, 2003
[Hormonal replacement therapy in postmenopausal women in Spain]Juan Rubiés-Prat, Juan Pedro-Botet
Medicina Clinica|July 28, 2004
[Looking for the cardiovascular risk]Juan Pedro-Botet, Juan Rubiés Prat
Medicina Clinica|May 15, 2004
[Advanced age, lipoproteic profile and cardiovascular risk]Juan Rubiés-Prat, Juan Pedro-Botet
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|February 10, 2019
Statin treatment and increased diabetes risk. Possible mechanismsElisenda Climent, David Benaiges, Juan Pedro-Botet
Pageof 24

Showing results (11-20 of 240) with videos related to

Sort By:
Pageof 24
Obesity (Silver Spring, Md.)|January 11, 2018
Neurotensin and Nonalcoholic Fatty Liver Disease: Beyond ObesityJuan Pedro-Botet, David Benaiges
Medicina Clinica|March 12, 2020
LDL cholesterol in one stepJuan Pedro-Botet, Elisenda Climent
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|November 26, 2021
Warning: a short circuit has been detected in the prescription of PCSK9 inhibitorsJuan Pedro-Botet, Elisenda Climent
Medicina Clinica|March 15, 2003
[Hypertriglyceridemia as a cardiovascular risk factor. The end of a controversy?]Juan Rubiés-Prat, Juan Pedro-Botet
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|May 10, 2021
Therapeutic targets in the treatment of dyslipidaemias: From statins to PCSK9 inhibitors. Unmet needsJosé López-Miranda, Juan Pedro-Botet
Lancet (London, England)|May 7, 2017
Statin-associated muscle symptoms: beware of the nocebo effectJuan Pedro-Botet, Juan Rubiés-Prat
Medicina Clinica|February 28, 2003
[Hormonal replacement therapy in postmenopausal women in Spain]Juan Rubiés-Prat, Juan Pedro-Botet
Medicina Clinica|July 28, 2004
[Looking for the cardiovascular risk]Juan Pedro-Botet, Juan Rubiés Prat
Medicina Clinica|May 15, 2004
[Advanced age, lipoproteic profile and cardiovascular risk]Juan Rubiés-Prat, Juan Pedro-Botet
Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis|February 10, 2019
Statin treatment and increased diabetes risk. Possible mechanismsElisenda Climent, David Benaiges, Juan Pedro-Botet
Pageof 24